Sort
11,323 grants matching “glioblastoma”
Characterization of MET alteration using glioblastoma patient-derived xenograft models
$71,292Qian Xie · East Tennessee State University · R03 · FY2021 · NS
Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma
$71,260Kristin R Swanson · Mayo Clinic Arizona · U01 · FY2020 · CA
Medical Images for BiospecimensThe Task Order is in the amount of $71,250.00
$71,250Maciej Wiznerowicz · Internat'L Institute/Molecular Oncology · N02 · FY2017 · CA
Feasibility of gamma/delta T cell immunotherapy for glioblastoma
$71,200Lawrence S Lamb · University Of Alabama At Birmingham · R21 · FY2009 · NS
Cyclotron and Radiochemistry Specialized Resource
$71,181Nagichettiar Satyamurthy · University Of California Los Angeles · P50 · FY2012 · CA
Program 11: Cancer Immunology
$71,143Arlene H Sharpe · Dana-Farber Cancer Inst · P30 · FY2021 · CA
Program 11: Cancer Immunology
$71,030Arlene H Sharpe · Dana-Farber Cancer Inst · P30 · FY2020 · CA
Multivalent Inhibition of Integrin alphaVbeta3
$70,987Stewart Durell · Division Of Basic Sciences - Nci · ZIC · FY2011 · CA
Phase I Trial of Radiation and Lenalidomide in Pediatric Malignant Glioma
$70,976Katherine E Warren · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Development Research Project
$70,695Tracy T Batchelor · Massachusetts General Hospital · P50 · FY2017 · CA
Career Development Research Project
$70,695Tracy T Batchelor · Massachusetts General Hospital · P50 · FY2017 · CA
Ohio State Neuroscience Center Core
$70,478Balveen Kaur · Ohio State University · P30 · FY2013 · NS
Mismatch Repair Proteins as Drivers of Temozolomide Resistance in Glioblastoma
$70,458Adam Nathaniel Boynton · Dana-Farber Cancer Inst · F32 · FY2021 · CA
A systems approach to understanding overall drug response in a heterogeneous tumor-cell population
$70,458James Hyun-Woo Park · Institute For Systems Biology · F32 · FY2021 · CA
Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial
$70,423Alireza Mansouri · Pennsylvania State Univ Hershey Med Ctr · R03 · FY2022 · CA
Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial
$70,423Alireza Mansouri · Pennsylvania State Univ Hershey Med Ctr · R03 · FY2023 · CA
NEUROLOGIC ONCOLOGY
$70,257Mitchel S. Berger · University Of California, San Francisco · P30 · FY2010 · CA
Cancer Pharmacology
$70,137Xiaofeng Steven Zheng · Rutgers Biomedical And Health Sciences · P30 · FY2023 · CA
Targeting MELK-mediated EZH2 signaling in glioma stem cells
$70,084Ichiro Nakano · Ohio State University · R01 · FY2015 · NS
EGFR MEDIATED APOPTOSIS IN GLIOMAS
$70,070University Of Texas Sw Med Ctr/Dallas · K08 · FY2003 · CA
Immunology & Cancer Immunotherapy (ICI)
$70,043Charles L Sentman · Dartmouth College · P30 · FY2015 · CA
Immunology & Cancer Immunotherapy (ICI)
$70,043Mary J Turk · Dartmouth College · P30 · FY2019 · CA
Immuno/Oncology (IO)
$70,009Scott J Antonia · Duke University · P30 · FY2025 · CA
Cadherin-11 in cancer and rheumatoid arthritis, common target, common therapies
$69,975Stephen W Byers · Georgetown University · R01 · FY2014 · CA
Targeting purine biosynthesis to radiosensitize glioblastoma
$69,773Andrew Joseph Scott · University Of Michigan At Ann Arbor · F32 · FY2022 · CA